74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Zoetis Inc
Closed
Sector Healthcare
160.43 1.84
Overview
Share price change
24h
Min
160.08
Max
160.86
Income | -101M 581M |
|---|---|
Sales | -83M 2.3B |
P/E Sector Avg | 28.636 73.394 |
EPS | 1.4 |
Dividend yield | 1.28 |
Profit margin | 25.076 |
Employees | 13,800 |
EBITDA | -133M 906M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +29 upside |
Dividend yield Sector Avg | 1.28% 3.09% |
|---|---|
Next Earnings | 1 May 2025 |
Next Dividend date | 4 Mar 2025 |
Next Ex Dividend date | 21 Apr 2025 |
Market Cap | -8.7B 70B |
|---|---|
Previous open | 158.59 |
Previous close | 160.43 |
News Sentiment
By Acuity
39%
61%
127 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Zoetis Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zoetis Inc Forecast
Price Target
By TipRanks
29% upside
12 Months Forecast
Average 207 USD 29%
High 242 USD
Low 180 USD
Based on 8 Wall Street analysts offering 12 month price targets forZoetis Inc - Dist in the last 3 months.
Sentiment
By Acuity
127 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zoetis Inc
Zoetis Inc. is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products, biodevices, genetic tests and precision livestock farming technology. The Company has a business, commercializing products across eight core species: dogs, cats and horses (collectively, companion animals) and cattle, swine, poultry, fish and sheep (collectively, livestock); and within product categories such as vaccines, anti-infectives, parasiticides, dermatology, other pharmaceutical products, medicated feed additives and animal health diagnostics. The Company's segments include the United States and International. Within each of these operating segments, it offers a product portfolio for both livestock and companion animal customers.
